CD274 and non-small cell lung carcinoma: While these studies showed no effect for older age on response to ICI or on ICI-associated toxicities, another retrospective study evaluated 245 patients with NSCLC-treated PD1/PD-L1 inhibitors, revealing that both median progression-free survival (mPFS) and overall survival (mOS) differed by age (mPFS for <69 years: 2.53 months vs 3.75 months for ≥70 years, P = .055; and mOS for <69 years: 14.56 months vs. 12.92 months for ≥70 years, P = .011, respectively), while rates of toxicity remained similar across age groups.15